Animal Health Solutions

Works fast 1 Simple once-daily dosing No loading or tapering, minimizing the opportunity for rebound of itch 1 Zenrelia helps dogs achieve clinical remission of itch (PVAS <2). 1 Continuous efficacy Works over the long term, also significantly reducing lesions and inflammation 1 Zenrelia is a treatment for canine allergic itch and inflammation that provides fast and effective relief with just once-daily dosing from the very start. 1 Zenrelia is indicated for the control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age. INDICATIONS Zenrelia is indicated for control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age. IMPORTANT SAFET Y INFORMATION Read the entire package insert before using this drug, including the Boxed Warning. For Full prescribing information call 1 888 545 5973 or visit www.elancolabels.com/us/zenrelia. WARNING: VACCINE-INDUCED DISEASE AND INADEQUATE IMMUNE RESPONSE TO VACCINES. Based on results of the vaccine response study, dogs receiving Zenrelia are at risk of fatal vaccine-induced disease from modified live virus vaccines and inadequate immune response to any vaccine. Discontinue Zenrelia for at least 28 days to 3 months prior to vaccination and withhold Zenrelia for at least 28 days after vaccination. Dogs should be up to date on vaccinations prior to starting Zenrelia. Do not use in dogs less than 12 months old or dogs with a serious infection. Monitor dogs for infections because Zenrelia may increase susceptibility to opportunistic infections. Neoplastic conditions (benign and malignant) were observed during clinical studies. Consider the risks and benefits of treatment in dogs with a history of recurrence of these conditions. The most common adverse reactions were vomiting, diarrhea and lethargy. Zenrelia has not been evaluated in breeding, pregnant, or lactating dogs and concurrent use with glucocorticoids, cyclosporine, or other systemic immunosuppressive agents has not been tested. For full prescribing information see package insert. 1 Forster S, Boegel A, Despa S, et al. Comparative efficacy and safety of ilunocitinib and oclacitinib for the control of pruritus and associated skin lesions in dogs with atopic dermatitis. Get dogs back to normal with Zenrelia Visit ZenreliaForVets.com Works fast 1 Simple once-daily dosing No loading or tapering, minimizing the opportunity for rebound of itch 1 Zenrelia helps dogs achieve clinical remission of itch (PVAS <2). 1 Continuous efficacy Works over the long term, also significantly reducing lesions and inflammation 1 Zenrelia is a treatment for canine allergic itch and inflammation that provides fast and effective relief with just once-daily dosing from the very start. 1 Zenrelia is indicated for the control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age. INDICATIONS Zenrelia is indicated for control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age. IMPORTANT SAFET Y INFORMATION Read the entire package insert before using this drug, including the Boxed Warning. For Full prescribing information call 1 888 545 5973 or visit www.elancolabels.com/us/zenrelia. WARNING: VACCINE-INDUCED DISEASE AND INADEQUATE IMMUNE RESPONSE TO VACCINES. Based on results of the vaccine response study, dogs receiving Zenrelia are at risk of fatal vaccine-induced disease from modified live virus vaccines and inadequate immune response to any vaccine. Discontinue Zenrelia for at least 28 days to 3 months prior to vaccination and withhold Zenrelia for at least 28 days after vaccination. Dogs should be up to date on vaccinations prior to starting Zenrelia. Do not use in dogs less than 12 months old or dogs with a serious infection. Monitor dogs for infections because Zenrelia may increase susceptibility to opportunistic infections. Neoplastic conditions (benign and malignant) were observed during clinical studies. Consider the risks and benefits of treatment in dogs with a history of recurrence of these conditions. The most common adverse reactions were vomiting, diarrhea and lethargy. Zenrelia has not been evaluated in breeding, pregnant, or lactating dogs and concurrent use with glucocorticoids, cyclosporine, or other systemic immunosuppressive agents has not been tested. For full prescribing information see package insert. 1 Forster S, Boegel A, Despa S, et al. Comparative efficacy and safety of ilunocitinib and oclacitinib for the control of pruritus and associated skin lesions in dogs with atopic dermatitis. Veterinary Dermatology. 2025; 1–10. Zenrelia, Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates. © 2025 Elanco or its affiliates. PM-US-24-1154(3) Get dogs back to normal with Zenrelia Visit ZenreliaForVets.com Works fast 1 Simple once-daily dosing No loading or tapering, minimizing the opportunity for rebound of itch 1 Zenrelia helps dogs achieve clinical remission of itch (PVAS <2). 1 Continuous efficacy Works over the long term, also significantly reducing lesions and inflammation 1 Zenrelia is a treatment for canine allergic itch and inflammation that provides fast and effective relief with just once-daily dosing from the very start. 1 Zenrelia is indicated for the control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age. INDICATIONS Zenrelia is indicated for control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age. IMPORTANT SAFET Y INFORMATION Read the entire package insert before using this drug, including the Boxed Warning. For Full prescribing information call 1 888 545 5973 or visit www.elancolabels.com/us/zenrelia. WARNING: VACCINE-INDUCED DISEASE AND INADEQUATE IMMUNE RESPONSE TO VACCINES. Based on results of the vaccine response study, dogs receiving Zenrelia are at risk of fatal vaccine-induced disease from modified live virus vaccines and inadequate immune response to any vaccine. Discontinue Zenrelia for at least 28 days to 3 months prior to vaccination and withhold Zenrelia for at least 28 days after vaccination. Dogs should be up to date on vaccinations prior to starting Zenrelia. Do not use in dogs less than 12 months old or dogs with a serious infection. Monitor dogs for infections because Zenrelia may increase susceptibility to opportunistic infections. Neoplastic conditions (benign and malignant) were observed during clinical studies. Consider the risks and benefits of treatment in dogs with a history of recurrence of these conditions. The most common adverse reactions were vomiting, diarrhea and lethargy. Zenrelia has not been evaluated in breeding, pregnant, or lactating dogs and concurrent use with glucocorticoids, cyclosporine, or other systemic immunosuppressive agents has not been tested. For full prescribing information see package insert. 1 Forster S, Boegel A, Despa S, et al. Comparative efficacy and safety of ilunocitinib and oclacitinib for the control of pruritus and associated skin lesions in dogs with atopic dermatitis. Veterinary Dermatology. 2025; 1–10. Zenrelia, Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates. © 2025 Elanco or its affiliates. PM-US-24-1154(3) Get dogs back to normal with Zenrelia Visit ZenreliaForVets.com Works fast 1 Simple once-daily dosing No loading or tapering, minimizing the opportunity for rebound of itch 1 Zenrelia helps dogs achieve clinical remission of itch (PVAS <2). 1 Continuous efficacy Works over the long term, also significantly reducing lesions and inflammation 1 Zenrelia is a treatment for canine allergic itch and inflammation that provides fast and effective relief with just once-daily dosing from the very start. 1 Zenrelia is indicated for the control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age. INDICATIONS Zenrelia is indicated for control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age. IMPORTANT SAFET Y INFORMATION Read the entire package insert before using this drug, including the Boxed Warning. For Full prescribing information call 1 888 545 5973 or visit www.elancolabels.com/us/zenrelia. WARNING: VACCINE-INDUCED DISEASE AND INADEQUATE IMMUNE RESPONSE TO VACCINES. Based on results of the vaccine response study, dogs receiving Zenrelia are at risk of fatal vaccine-induced disease from modified live virus vaccines and inadequate immune response to any vaccine. Discontinue Zenrelia for at least 28 days to 3 months prior to vaccination and withhold Zenrelia for at least 28 days after vaccination. Dogs should be up to date on vaccinations prior to starting Zenrelia. Do not use in dogs less than 12 months old or dogs with a serious infection. Monitor dogs for infections because Zenrelia may increase susceptibility to opportunistic infections. Neoplastic conditions (benign and malignant) were observed during clinical studies. Consider the risks and benefits of treatment in dogs with a history of recurrence of these conditions. The most common adverse reactions were vomiting, diarrhea and lethargy. Zenrelia has not been evaluated in breeding, pregnant, or lactating dogs and concurrent use with glucocorticoids, cyclosporine, or other systemic immunosuppressive agents has not been tested. For full prescribing information see package insert. 1 Forster S, Boegel A, Despa S, et al. Comparative efficacy and safety of ilunocitinib and oclacitinib for the control of pruritus and associated skin lesions in dogs with atopic dermatitis. Veterinary Dermatology. 2025; 1–10. Get dogs back to normal with Zenrelia Visit ZenreliaForVets.com

• Cover